2025
Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming
Zhou S, Wang K, Huang J, Xu Z, Yuan Q, Liu L, Wang Z, Miao J, Wang H, Wang T, Guan W, Ding C. Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming. Gut Microbes 2025, 17: 2508949. PMID: 40409349, PMCID: PMC12118437, DOI: 10.1080/19490976.2025.2508949.Peer-Reviewed Original ResearchConceptsIndole-3-lactic acidColorectal cancer patientsColorectal cancerAryl hydrocarbon receptorDownregulated glucose metabolismPotential clinical therapeutic targetsAnti-apoptotic capabilityInfluence tumor progressionGut microbiota metabolismTumor cell proliferationMetagenomic sequencingPhosphorylation sitesXenograft mouse modelGut microbiotaClinical therapeutic targetMetabolic reprogrammingMicrobiota metabolismP-STAT3Tumor progressionTumor malignancyMouse modelTryptophan metabolismCancer cellsIn vitro experimentsCRC developmentMitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway
Gao Y, Peng Y, Zhou Y, Zhu J, Fu S, Chen Y, Cai C, Han Y, Shen H, Zeng S, Mao L, Xiao Z. Mitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway. International Immunopharmacology 2025, 157: 114664. PMID: 40334626, DOI: 10.1016/j.intimp.2025.114664.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAnti-tumor immunityColorectal cancerResponse to immune checkpoint inhibitorsAssociated with worse overall survivalKaplan-Meier survival analysisProgression-free survivalTumor immune regulationMetastasis of colorectal cancerMitochondrial solute carriersMicrosatellite instabilityColorectal cancer cell linesColorectal cancer patientsCancer-related mortalityProliferation-related markersCheckpoint inhibitorsColorectal cancer progressionOverall survivalImmune infiltrationPotential therapeutic targetPrognostic markerUnfavorable prognosisColorectal cancer tissuesImmune regulationClinical cohortFamitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. The Innovation 2025, 6: 100745. PMID: 39872476, PMCID: PMC11763884, DOI: 10.1016/j.xinn.2024.100745.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseAdvanced colorectal cancerOverall survivalColorectal cancerMedian duration of responseMedian progression-free survivalMetastatic colorectal cancer patientsTreatment-related adverse eventsMedian follow-up timeMedian overall survivalMetastatic solid tumorsPD-1 antagonistsFollow-up timeCohort of patientsAnti-angiogenic agentsColorectal cancer patientsInhibition of angiogenesisPD-1Immune checkpointsMetastatic diseaseBasket studyMedian durationPrimary endpointSystemic treatment
2024
Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases
Kuhn T, Engelhardt W, Kahl V, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho J, Kawaguchi Y, Hasegawa K, Odisio B, Vauthey J, Antoch G, Chapiro J, Madoff D. Artificial Intelligence–Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. Journal Of Vascular And Interventional Radiology 2024, 36: 477-488. PMID: 39638087, DOI: 10.1016/j.jvir.2024.11.025.Peer-Reviewed Original ResearchTotal liver volumeMetastatic colorectal cancer patientsPreoperative portal vein embolizationColorectal cancer liver metastasesPortal vein embolizationCancer liver metastasesMulticenter retrospective studyColorectal cancer patientsStudent's t-testBoard-certified radiologistsVein embolizationConsecutive patientsLiver metastasesLiver volumePatient selectionRetrospective studyCancer patientsRadiomic featuresInclusion criteriaPatientsSemi-automatic segmentationLab valuesT-testSDAUCEvaluation of completeness of commonly used data elements for clinical trial eligibility criteria using a registry-enhanced data collection process: Results from patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) at three community oncology practices.
Campbell Fontaine A, McAneny B, Tucker V, Koontz M, Trotter C, Paulson J, McMurdie P, Tezcan A, Peguero J, Peguero J, Campos L. Evaluation of completeness of commonly used data elements for clinical trial eligibility criteria using a registry-enhanced data collection process: Results from patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) at three community oncology practices. Journal Of Clinical Oncology 2024, 20: 346-346. DOI: 10.1200/op.2024.20.10_suppl.346.Peer-Reviewed Original ResearchNon-small cell lung cancerCommunity oncology practicesColorectal cancerDiagnosis dateOncology practiceCancer diagnosisData elementsEligibility assessmentColorectal cancer patientsCompletion ratesGenomic test resultsEssential data elementsLung cancerClinical trialsRemote staffMale to female ratioSystemic anti-cancer treatmentTrial eligibility criteriaPatient identificationECOG performance statusICD10 codesPatient RegistryYears of ageLung cancer diagnosisCell lung cancer577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Christenson E, Kazmi S, Mahadevan D, Sohal D, Manda S, Martz A, Kordahi S, Zika M, Kothari P, Kahan S, Barbu E, Morawski A, Flies D, Langermann S, Chisamore M, Fu S, Wadlow R, Guha U, Myint H, Le D. 577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients. Annals Of Oncology 2024, 35: s468. DOI: 10.1016/j.annonc.2024.08.646.Peer-Reviewed Original ResearchPre‐diagnostic plasma advanced glycation end‐products and soluble receptor for advanced glycation end‐products and mortality in colorectal cancer patients
Li J, Baker J, Aglago E, Zhao Z, Jiao L, Freisling H, Hughes D, Eriksen A, Tjønneland A, Severi G, Katzke V, Kaaks R, Schulze M, Masala G, Pala V, Pasanisi F, Tumino R, Padroni L, Vermeulen R, Gram I, Braaten T, Jakszyn P, Sánchez M, Gómez‐Gómez J, Moreno‐Iribas C, Amiano P, Papier K, Weiderpass E, Huybrechts I, Heath A, Schalkwijk C, Jenab M, Fedirko V. Pre‐diagnostic plasma advanced glycation end‐products and soluble receptor for advanced glycation end‐products and mortality in colorectal cancer patients. International Journal Of Cancer 2024, 155: 1982-1995. PMID: 39057841, DOI: 10.1002/ijc.35114.Peer-Reviewed Original ResearchConceptsAssociated with CRC-specificAdvanced glycation end productsPlasma advanced glycation end productsColorectal cancerCRC-specificOverall mortalityGlycation end productsSoluble receptorCancer patientsIntracellular signaling alterationsMultivariable-adjusted Cox proportional hazards regressionCancer and NutritionCox proportional hazards regressionEuropean Prospective InvestigationFollow-up periodColorectal cancer casesColorectal cancer patientsProportional hazards regressionUltra-performance liquid chromatography mass spectrometryColorectal cancer diagnosisEnzyme-linked immunosorbent assayColorectal cancer survivalProspective InvestigationChronic inflammationSRAGEAbstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases
Zhao J, Ong J, Chia D, Teo M, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Tan P, Sundar R. Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases. Cancer Research 2024, 84: 2759-2759. DOI: 10.1158/1538-7445.am2024-2759.Peer-Reviewed Original ResearchColorectal cancer peritoneal metastasesCRC PMPeritoneal metastasisColorectal cancerIntra-tumor heterogeneitySystemic regimensTherapeutic targetAmerican Association for Cancer Research annual meetingsPrognosis of peritoneal metastasisResistant to systemic chemotherapyPlasma-peritoneal barrierOncological surgical resectionColorectal cancer patientsSystemic chemotherapySurgical resectionPalliative surgerySystemic therapyAntineoplastic therapyPotential therapeutic targetExploratory laparotomyTranscoelomic metastasisPoor prognosisFFPE tissue samplesSynchronous PMPoor responseFinancial toxicity of informal caregivers of colorectal cancer patients: A cross-sectional study
Zhang M, Wang X, Shao M, Li T, Guo S, Yang Y, Yu L, Bin M, Li D, Zhou H, Yao L, Chen C, Wang T. Financial toxicity of informal caregivers of colorectal cancer patients: A cross-sectional study. European Journal Of Oncology Nursing 2024, 69: 102519. PMID: 38402718, DOI: 10.1016/j.ejon.2024.102519.Peer-Reviewed Original ResearchConceptsLevels of financial toxicityFinancial toxicity scoresFinancial toxicitySocial supportPerceived stressColorectal cancer patientsQuality of colorectal cancer careEffects of financial toxicityCancer patientsColorectal cancer careHigh social supportCross-sectional studyInformal caregiversCaregiver ageMultivariate linear regressionCancer careAverage household incomeCaregiversTargeted interventionsMedical insuranceHousehold incomeMultivariate regression analysisMedical costsSurvey designIncreased communicationA phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz H, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, Khoueiry A, Azad N. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal Of Cancer 2024, 154: 1794-1801. PMID: 38312102, DOI: 10.1002/ijc.34845.Peer-Reviewed Original ResearchRefractory to irinotecanArm ATAS-102DNA methyltransferase inhibitorArm BRates of progression free survivalB. Median overall survivalEvidence of target modulationMetastatic colorectal cancer patientsResistant to systemic therapyTreatment related adverse eventsProgression free survivalPhase II studyPhase II trialKaplan-Meier ratesRelated adverse eventsColorectal cancer patientsFree survivalOverall survivalSystemic therapyAdverse eventsIrinotecanRegorafenibCancer patientsGuadecitabine
2023
Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer
Zhang W, Sun R, Hu X, Chen Z, Lai C. Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer. World Journal Of Surgical Oncology 2023, 21: 299. PMID: 37735407, PMCID: PMC10512522, DOI: 10.1186/s12957-023-03183-7.Peer-Reviewed Original ResearchConceptsCaprini risk assessment modelLow-molecular-weight heparinLaparoscopic radical resection of colorectal cancerResection of colorectal cancerRadical resection of colorectal cancerLaparoscopic radical resectionLMWH groupD-dimerDeep vein thrombosisCut-off valueVein thrombosisROC curveColorectal cancerIPC groupClinical data of patientsLow incidence of thrombosisOccurrence of deep vein thrombosisAccurate risk stratificationDecision curve analysisData of patientsColorectal cancer patientsIncidence of thrombosisIncidence of DVTMolecular weight heparinArea under the ROC curveIntegrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality
Zhou J, pour A, Deirawan H, Daaboul F, Aung T, Beydoun R, Ahmed F, Chuang J. Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality. EBioMedicine 2023, 94: 104726. PMID: 37499603, PMCID: PMC10388166, DOI: 10.1016/j.ebiom.2023.104726.Peer-Reviewed Original ResearchConceptsModerate-risk patientsClinical variablesPatient stratificationOverall survivalAdenocarcinoma patientsTCGA-COADLow-risk patientsColorectal cancer patientsEnrollment of patientsRectal adenocarcinoma patientsRisk of mortalityColon adenocarcinoma patientsLow immune infiltrationNational Cancer InstituteMutation signaturesNumber of deathsCancer Genome AtlasColorectal cancerPathological featuresCancer patientsImmune infiltrationImproved stratificationClinical trialsPatient riskCancer InstituteThe genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Lustberg M, Kaneva K, Teslow E, Mauer E, Federman N, Eisfeld A. The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing. Journal Of Clinical Oncology 2023, 41: e15091-e15091. DOI: 10.1200/jco.2023.41.16_suppl.e15091.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor mutational burdenCancer patientsAYA patientsMicrosatellite instabilityBreast cancerNext-generation sequencingYoung adult cancer patientsYoung adult malignancyColorectal cancer patientsAdult cancer patientsHER2- breast cancerOlder adult patientsAYA cancer patientsSoft tissue sarcomasCentral nervous systemHigh-grade gliomasLow-grade gliomasPathogenic single nucleotide variantsAYA cancerSingle nucleotide variantsAdult patientsGastrointestinal malignanciesNTRK fusionsAML subgroupsA study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
Baretti M, Murphy A, Zahurak M, Gianino N, Parkinson R, Walker R, Lopez-Vidal T, Zheng L, Rosner G, Ahuja N, Kurt S, Azad N. A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clinical Epigenetics 2023, 15: 74. PMID: 37120591, PMCID: PMC10149019, DOI: 10.1186/s13148-023-01485-x.Peer-Reviewed Original ResearchConceptsColorectal cancer patientsAdvanced colorectal cancer patientsImmune checkpoint inhibitor therapyMedian progression-free survivalDurable partial responseHematological adverse eventsMMR-proficient tumorsCheckpoint inhibitor therapyAdvanced colorectal cancerProgression-free survivalImmune cell infiltrationHistone deacetylasesImmunologic shiftCheckpoint inhibitorsRECIST criteriaAdverse eventsCheckpoint therapyOverall survivalPartial responseInhibitor therapyMedian ageColorectal cancerFurther mechanistic investigationsCancer patientsCell infiltrationDiscovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan H, Talty R, Jain A, Cai Y, Zheng J, Shen X, Muca E, Paty P, Bosenberg M, Khan S, Johnson C. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations. Redox Biology 2023, 62: 102699. PMID: 37086630, PMCID: PMC10172914, DOI: 10.1016/j.redox.2023.102699.Peer-Reviewed Original ResearchConceptsKRAS mutant tumorsMale CRC patientsCRC patientsMale patientsKRAS mutationsMutant tumorsOverall survivalMale colorectal cancer patientsKRAS wild-type tumorsAberrant tumor metabolismColorectal cancer patientsCRC patient cohortsColorectal cancer casesFerroptosis-related genesWild-type tumorsNovel potential avenuesNormal colon tissuesPoor OSKRAS statusAdverse outcomesCRC cellsPatient cohortCancer patientsType tumorsCancer casesMalignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer.
Gwee Y, Chia D, Provenzano L, Lonardi S, Conca V, Cremolini C, Yong W, Tan P, So J, Kim G, Shabbir A, Ong J, Pietrantonio F, Sundar R. Malignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer. Journal Of Clinical Oncology 2023, 41: 455-455. DOI: 10.1200/jco.2023.41.4_suppl.455.Peer-Reviewed Original ResearchPeritoneal cancer indexPresence of malignant ascitesPeritoneal metastasisMalignant ascitesColorectal cancer patientsGastric cancerColorectal cancerOverall survivalGastrointestinal malignanciesPoor survivalCohort of gastric cancerMedian peritoneal cancer indexPeritoneal cancer index scoreFirst-line systemic treatmentResistant to systemic therapyMetastatic gastrointestinal malignanciesMedian overall survivalStage IV diseaseMetastatic CRC patientsAbsence of ascitesClinico-pathological dataPoor survival outcomesTertiary oncology centerStudy of patientsRandomized clinical trials
2022
Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer
Li C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakih M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. Communications Medicine 2022, 2: 90. PMID: 35856081, PMCID: PMC9287310, DOI: 10.1038/s43856-022-00155-y.Peer-Reviewed Original ResearchMetastatic colorectal cancerExperimental armColorectal cancerMetastatic colorectal cancer (mCRC) trialsMetastatic colorectal cancer patientsPhase Ib/IITrial dataHistorical trial dataColorectal cancer trialsDisease control rateObjective response ratePhase 3 trialProgression-free survivalColorectal cancer patientsStandardized mortality ratioEarly phase trialsEarly phase clinical developmentLogistic regression modelsMultiple experimental armsPrimary endpointOverall survivalPrior linesEfficacy signalsSafety profileCombination therapy
2021
Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers
Cheng E, Soulos PR, Irwin ML, Feliciano E, Presley CJ, Fuchs CS, Meyerhardt JA, Gross CP. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. JAMA Network Open 2021, 4: e2139593. PMID: 34919133, PMCID: PMC8683967, DOI: 10.1001/jamanetworkopen.2021.39593.Peer-Reviewed Original ResearchConceptsCancer-specific mortalityNeighborhood socioeconomic statusIndividual-level socioeconomic statusIndividual socioeconomic statusColorectal cancerOverall mortalitySocioeconomic statusCohort studyHazard ratioDual eligibilityCancer patientsCommon cancerLung cancerProstate cancerSocioeconomic disadvantageHigh riskEnd Results-Medicare databaseMedicare-Medicaid dual eligibilityPopulation-based cohort studyCox proportional hazards regressionSuboptimal cancer careColorectal cancer patientsBreast cancer patientsProportional hazards regressionNon-Hispanic white individualsImmune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Liu J, Huang X, Liu H, Wei C, Ru H, Qin H, Lai H, Meng Y, Wu G, Xie W, Mo X, Johnson CH, Zhang Y, Tang W. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients. Journal Of Translational Medicine 2021, 19: 27. PMID: 33413474, PMCID: PMC7789428, DOI: 10.1186/s12967-020-02638-9.Peer-Reviewed Original ResearchConceptsKRAS mutant CRC patientsTumor-infiltrating immune cellsKRAS wild-type CRC patientsCD4 memory T cellsCRC patientsMemory T cellsColorectal cancerT cellsImmune pathwaysImmune cellsMacrophage M1Hypersensitive C-reactive proteinKRAS-mutant colorectal cancerCases of CRCKRAS mutantPrognostic immune-related genesImmune risk modelColorectal cancer patientsRegulatory T cellsC-reactive proteinTumor immune microenvironmentDistinct clinical outcomesT cell receptorImmune-related genesConclusionsKRAS mutation
2020
22 Poster Discussion A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)
Lee V, Zahurak M, Cercek A, Verheul H, Lenz H, Jones P, Baylin S, Parkinson R, Rami V, Lilly E, Miles T, Brown T, Ahuja N, Khoueiry A, Azad N. 22 Poster Discussion A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts). European Journal Of Cancer 2020, 138: s12. DOI: 10.1016/s0959-8049(20)31096-0.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply